ADMA Biologics (NASDAQ:ADMA) Share Price Crosses Below 200 Day Moving Average – Time to Sell?

ADMA Biologics Inc (NASDAQ:ADMA) passed below its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $10.93 and traded as low as $10.25. ADMA Biologics shares last traded at $10.48, with a volume of 13,368,485 shares traded.

More ADMA Biologics News

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: ADMA reported third-quarter revenue of $141.1 million, above the roughly $138.1 million consensus, and earnings of about $0.22–$0.23 per share, ahead of estimates. Profit increased year over year, with growth in ASCENIV helping drive the results. MarketWatch article
• Positive Sentiment: The company reaffirmed its forecast for at least $530 million in 2026 revenue and raised its minimum adjusted EBITDA outlook to at least $275 million, citing accelerating ASCENIV demand. This stronger profit outlook may support investor expectations for growth. Seeking Alpha article
• Positive Sentiment: Canaccord Genuity maintained its Buy rating. Separately, ADMA moved above its 20-day and 200-day moving averages, which technical-focused investors may view as signs of improving short- and longer-term momentum. Globe and Mail article Zacks article on moving averages
• Neutral Sentiment: Cantor Fitzgerald raised its price target from $12 to $13 but kept a Neutral rating, suggesting the analyst sees limited near-term upside. Also, ASCENIV’s strength offset weaker Bivigam sales, leaving product performance mixed. International Business Times article

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Mizuho set a $18.00 target price on ADMA Biologics in a research report on Thursday. Weiss Ratings reiterated a “hold (c)” rating on shares of ADMA Biologics in a research note on Monday, September 14th. Zacks Research raised ADMA Biologics from a “strong sell” rating to a “hold” rating in a report on Wednesday, September 2nd. Finally, Cantor Fitzgerald increased their price objective on ADMA Biologics from $12.00 to $13.00 and gave the company a “neutral” rating in a report on Thursday. Three analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $17.50.

ADMA Biologics Stock Down 3.6%

The stock has a market cap of $2.85 billion, a price-to-earnings ratio of 15.58 and a beta of 0.65. The company has a current ratio of 6.97, a quick ratio of 3.81 and a debt-to-equity ratio of 0.49. The firm’s 50 day moving average is $10.21 and its two-hundred day moving average is $10.88.

ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Wednesday, November 4th. The biotechnology company reported $0.23 earnings per share for the quarter, topping the consensus estimate of $0.20 by $0.03. ADMA Biologics had a return on equity of 40.17% and a net margin of 32.98%. The business had revenue of $141.10 million for the quarter, compared to analyst estimates of $138.11 million. During the same period last year, the company posted $0.15 EPS. The business’s quarterly revenue was up 5.1% on a year-over-year basis. On average, sell-side analysts predict that ADMA Biologics Inc will post 0.79 EPS for the current year.

Institutional Trading of ADMA Biologics

Several hedge funds have recently added to or reduced their stakes in the business. Royal Bank of Canada increased its position in ADMA Biologics by 448.8% during the 1st quarter. Royal Bank of Canada now owns 929,326 shares of the biotechnology company’s stock worth $8,373,000 after buying an additional 759,984 shares during the period. Bank of America Corp DE boosted its position in shares of ADMA Biologics by 107.5% in the first quarter. Bank of America Corp DE now owns 3,997,675 shares of the biotechnology company’s stock valued at $36,019,000 after acquiring an additional 2,071,338 shares during the period. Odyssean LLC bought a new stake in shares of ADMA Biologics in the second quarter valued at about $1,042,000. Velan Capital Investment Management LP bought a new stake in shares of ADMA Biologics in the second quarter valued at about $2,092,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of ADMA Biologics in the second quarter valued at about $10,468,000. Institutional investors own 75.68% of the company’s stock.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company focused on developing, manufacturing and commercializing plasma-derived biologic products for people with compromised or weakened immune systems. The company’s activities include collecting human plasma, developing immune globulin therapies and manufacturing products for use in the prevention and treatment of certain infectious diseases.

ADMA’s portfolio includes Asceniv, an intravenous immune globulin indicated for primary humoral immunodeficiency disease, and Bivigam, an intravenous immune globulin used for the treatment of primary humoral immunodeficiency.